A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY
A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY
This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), who have been prescribed ocrelizumab as per routine practice. This study will use a comprehensive combination of participant reported outcomes and conventional multiple sclerosis (MS) endpoints that measure clinical domains commonly affected by MS (e.g. fatigue, hand function, gait, cognition), and their impact on employment, activities of daily living, quality of life and healthcare resource utilization. The incidence, type, and pattern of serious adverse events (SAEs), and of adverse events (AEs) leading to treatment discontinuation will also be determined.
Inclusion Criteria:
Exclusion Criteria:
Mont-godinne, 5530, Belgium
Santo Domingo, DUMMY_VALUE, Dominican Republic
Rome, Lazio 00133, Italy
Pavia, Lombardy 27100, Italy
Torrette - Ancona, The Marches 60100, Italy
NL -rotterdam, 3079 DZ, Netherlands
Głogów Małopolski, 36-060, Poland
Moscow, Moscow Oblast 117186, Russia
Santiago de Compostela, LA Coruna 15706, Spain
Dubai-UAE, DUMMY_VALUE, United Arab Emirates
Westbury-on-Trym, Bristol, BS10 5NB, United Kingdom